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ABSTRACT 
 The thyroid gland consists of two types of cells that develop from distinct 
tissues. The parafollicular C-cells are derived from neural crest tissue and 
produce calcitonin, while the follicular cells produce thyroid hormone and are 
derived from endodermal tissue; thyroid hormone is the focus of this study. In the 
follicular cells, iodide is eventually metabolized into T4 and T3, with T4 being the 
primary production. Deiodinase 2 processes T4 into T3 because T3 serves the 
greatest physiological function. Thyroid hormone is crucial in maintaining basal 
metabolic rate and has a major effect on many organs, so in order for the body to 
optimally operate, thyroid hormone must be produced and utilized in a proper 
manner. However, the role of thyroid hormone in wound healing has not been 
properly addressed.  
 The main steps in wound healing involve migration, proliferation, 
remodeling, and angiogenesis. Fibroblasts play a key role in all of these steps 
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and hence, were the cells of choice in this study. Platelet derived growth factor-
BB is critical in wound healing because it is potent in causing both the 
proliferation and migration of fibroblasts. In this study, we dosed fibroblasts with 
different concentrations of thyroid hormone in an attempt to see if the expression 
of PDGF-BB increased in fibroblasts dosed with thyroid hormone. Fibroblasts 
were passed, dosed with T3, lysed, and western blots were run to see if the 
expression of PDGF-BB changed depending on the concentration of T3. 
 Previous studies conducted on mice and guinea pigs showed that an 
application of topical thyroid hormone cream onto wounds resulted in quicker 
healing. The next step is to find the individual mechanisms and proteins that 
thyroid hormone affects, using western blots. The T3 concentrations utilized were 
10-7 M and 10-8 M and a control was used that contained fibroblasts with no 
thyroid hormone. The western blot films clearly showed an increase in the 
expression of PDGF-BB with the 10-7 M and 10-8 M fibroblasts compared to the 
control group. Thus, thyroid hormone could affect the migration and proliferation 
steps of wound healing through the expression of PDGF-BB. Unfortunately, this 
expression did not appear to be dose-dependent since the samples with less 
thyroid hormone, 10-8 M, contained an equal or heavier band than the 10-7 M 
samples. Hence, more experiments need to be run with more concentrations in 
order to obtain statistically significant data.  
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INTRODUCTION 
The Thyroid Gland 
 Before exploring the topics of thyroid hormone and wound healing, it is 
crucial to first explore the thyroid gland itself. The thyroid gland is unique in 
structure, function and location. The gland itself is located at the front of the neck 
directly underneath the larynx, which is also known as the voice box. There are 
actually two sections, or lobes, of the thyroid gland and each lobe is located on 
either side of the trachea. The entire thyroid is a two-inch structure, with both 
lobes connected by the isthmus (Ross and Pawlina, 2011). 
 One unique aspect of the thyroid lies in the fact that the gland develops 
from two different embryonic tissues. The two different cells that comprise the 
thyroid are known as follicular cells and parafollicular C-cells (Mansouri et al., 
1998). Furthermore, both the follicular cells and parafollicular C-cells have 
separate roles, in that each produces separate hormones. The follicular cells are 
developed from endodermal tissue, while the parafollicular C-cells are developed 
from neural crest tissue (Mansouri et al., 1998). Although the precise 
mechanisms of the development of each cell type are not yet known, there has 
been research into the specific genes that are necessary for the proper 
development of each cell. It has been shown that the transcription factor Ttf1 is 
completely necessary for the development of the thyroid. In mice missing the 
transcription factor Ttf1, neither follicular cells nor parafollicular C-cells were 
produced and the entire thyroid gland itself was not developed (Mansouri et al., 
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1998). In addition, following experiments run on mice, it has been presented that 
in order for follicular cells to properly develop, the Pax8 gene must also be 
present. Through unknown mechanisms, the Pax8 gene allows the endodermal 
embryonic tissue to develop into the follicular cells of the thyroid gland. When the 
Pax8 gene was removed from mice, the thyroid gland did not develop properly. 
The gland was significantly smaller in mice lacking the Pax8 gene, compared to 
the control group of the mice, and there were no follicular cells found; the thyroid 
gland consisted strictly of parafollicular C-cells. Even though the Pax8 gene was 
removed, there were no defects in any other organs that usually express Pax8. 
This most likely occurred because there are other Pax genes that were sufficient 
for these organs, such as the kidney, to develop, which is not the case for the 
thyroid gland. Different Pax genes are expressed in other glands that are derived 
from endodermal tissue, like the pancreas (Mansouri et al., 1998). Hence, the 
development of the thyroid gland may shed some light on different glands as 
well.  
As previously mentioned, both the follicular cells and the parafollicular C-
cells have separate functions. In a normal individual, the parafollicular C-cells 
only have a minor contribution to the thyroid. The function of these cells is to 
produce calcitonin, which plays a role in calcium regulation. The principal role of 
the thyroid gland is to produce thyroid hormone, which occurs in the follicular 
cells. Iodide is metabolized in these cells and results in the production of thyroid 
hormone and this hormone affects a vast array of tissues in the body (Antonica et 
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al., 2012). The specifics dealing with both the production and function of thyroid 
hormone will be explained later in this paper.  
 The thyroid gland, like other glandular organs, is controlled by the 
hypothalamus-pituitary axis. The pituitary gland receives blood from the 
hypothalamus through a portal system and the pituitary then controls the release 
of hormones in many glandular organs, such as the thyroid (Drigo and Bianco, 
2011). For example, the thyroid gland is controlled by thyroid stimulating 
hormone, or TSH, which is released from the pituitary. TSH is released in 
response to thyrotropin-releasing hormone, or TRH, released by the 
hypothalamus, but also controlled by levels of thyroid hormone. The 
paraventricular nucleus neurons of the medial basal hypothalamus produce TRH 
(Drigo and Bianco, 2011). TRH is then released through the portal blood, where it 
reaches the pituitary and causes a feedback mechanism in the pituitary. When 
TRH binds to receptors in the pituitary, TSH is released from the pituitary and this 
causes an increase in both the production and secretion of thyroid hormone in 
the thyroid gland (Drigo and Bianco, 2011).  
Since the hypothalamus-pituitary axis controls the production and release 
of thyroid hormone, there must be a negative feedback to turn off the production 
of thyroid hormone. This negative feedback occurs through T3 and T4 (Mebis et 
al., 2009). When there are elevated levels of T4 and T3, they in turn participate in 
a negative feedback loop in order to stop the release of TRH and TSH. When 
there are increased levels of thyroid hormones, there is a decrease in the 
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expression of the TSHb gene in the pituitary, thereby decreasing the production 
and release of TSH. Contrary, when levels of thyroid hormone are low, TSHb 
expression is increased in the pituitary in order to increase the release of TSH 
and thyroid hormone. A similar feedback loop also occurs in the hypothalamus 
and the release of TRH is either increased or decreased based on the level of 
thyroid hormones (Drigo and Bianco, 2011). Figure 1 shows this axis and the 
feedback loop that controls the thyroid gland.  
 
 
Figure 1. The Hypothalamus-Pituitary-Thyroid Axis. The hypothalamus releases TRH, which 
causes the pituitary to release TSH, and in turn, causes the thyroid to produce and secrete 
thyroid hormone. Furthermore, the negative feedback loop on the anterior pituitary and 
hypothalamus and the roles of the deiodinases can also be seen (Drigo and Bianco, 2011).  
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Thyroid Hormone 
 
 There are two different forms of thyroid hormone, triiodothyronine, or T3, 
and thyroxine, or T4. Even though both T3 and T4 are produced in the thyroid 
gland, the majority of thyroid hormone secreted is in the form of T4 and as a 
result, T3 is formed from T4. Furthermore, T3 has a much greater physiological 
impact because it binds to the nuclear thyroid hormone receptors with ten times 
greater affinity (Oetting and Yen, 2007). 
 
Synthesis of Thyroid Hormone 
 As mentioned previously, the cells of the thyroid that synthesize thyroid 
hormone are the follicular cells. Also in the area of the follicular, or principal cells, 
are colloids and these colloids are made mainly of thyroglobulin. Thyroglobulin 
consists of iodinated tyrosine molecules that form activated thyroid hormone 
(Ross and Pawlina, 2011). Functional thyroid hormone is released into capillaries 
around the follicle from thyroglobulin after certain processing occurs. 
Thyroglobulin is produced in the rough endoplasmic reticulum of the principal 
cells. Before the thyroglobulin is packaged into vesicles and transported to the 
lumen of the follicle, it must be properly glycosylated in the Golgi apparatus and 
rough endoplasmic reticulum (Ross and Pawlina, 2011).  
 The actual production of T3 and T4 occurs after a number of key steps. 
Iodide is a key component of both T3 and T4 and without it they cannot be 
properly synthesized. The first step of the production is the movement of iodide 
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from the extracellular space into the follicular cell. This is occurs through 
secondary active transport across a sodium/iodide symporter, or NIS, that is 
independent of ATP (Ross and Pawlina, 2011). The iodide is transported into the 
basolateral membrane of the cells, then diffuses toward the apical cell membrane 
and is then transported into the follicular lumen. The transportation into the lumen 
occurs through pendrin, an iodide/chloride transporter. Immediately in the lumen, 
iodide is oxidized to iodine by thyroid peroxidase, or TPO. (Ross and Pawlina, 
2011). 
 After the oxidation to iodine, the next step involves the iodination of 
thyroglobulin. Thyroglobulin consists of tyrosine and one or two atoms of iodine 
are added to the tyrosine residues of thyroglobulin; this addition is specific. 
Thyroid peroxidase again catalyzes the reaction, which, occurs in the colloid. 
When one iodine molecule is added to one tyrosine, the result is 
monoiodotyrosine, or MIT. When two molecules are added to one tyrosine 
residue, diiodotyrosine is the resulting product, or DIT (Ross and Pawlina, 2011). 
 Once either MIT or DIT are synthesized, thyroid hormone can be 
produced either in the form of T3 or T4. This formation occurs when two-
iodinated tyrosine molecules are brought together and coupled. For example, 
when two DIT molecules undergo a coupling reaction, T4 is formed. When one 
DIT molecule and one MIT molecule are coupled together, the result is T3. After 
the formation of T3 and T4, much like DIT and MIT, they are stored in the colloid 
still attached to thyroglobulin in the lumen (Ross and Pawlina, 2011). Now that 
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there is stored thyroid hormone, there must be a way to release it from the 
colloid. In response to TSH, the follicular cells take up thyroglobulin through 
endocytosis. Thyroid hormone is released from the endocytotic vesicle when the 
vesicle fuses with cell lysosomes. Thyroglobulin is then degraded by the 
lysosomes, leaving free T3, T4, rT3, DIT, and MIT. Free T4 and T3 are free to 
leave the cell basally, in a ratio of 20:1 respectively, and enter capillaries where it 
can be carried to its destinations. Furthermore, free DIT and MIT lose the iodine 
molecules and the free iodine and tyrosine molecules can be recycled for further 
use (Ross and Pawlina, 2011). 
 As previously mentioned, the majority of thyroid hormone produced in the 
thyroid gland is in the form of T4. T4 is broken down into T3 using a deiodinase, 
which is a selenoenzyme (Köhrle, 1996). There are at least three different 
deiodinases found in the body. Deiodinases 1 and 2, also known as D1 and D2, 
participate in transforming T4 into the physiologically active T3 (Drigo and 
Bianco, 2011). Whereas D3 is used to deactivate both T3 and T4 so they can no 
longer have an effect on the body. These deiodinases exist in different tissues of 
the body and are crucial for maintaining optimal levels of thyroid hormone (Drigo 
and Bianco, 2011). Thyroid hormone travels in the blood mostly bound to carrier 
proteins. There are three different types of carrier proteins, which include, T4-
binding globulin, or TBG, albumin, and transthyretin or prealbumin (Glinoer, 
1997).  
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Effect of Thyroid Hormone 
 Thyroid hormone has many diverse biological effects; it is crucial for 
maintaining metabolic homeostasis, and for cell growth, development and 
differentiation (Song et al., 2011). In addition, the hormone binds to receptors 
located in the cell nucleus, TRalpha and TRbeta. Although these nuclear 
receptors are found in most cells of the body, brown fat and skeletal muscle 
contain more TRalpha, while the kidney, brain, and liver contain more TRbeta 
(Oetting and Yen, 2007). Thyroid hormone can have diverse effects because of 
the receptor isoforms. For example there exists numerous possibilities for 
heterodimeric partners and coregulators (Song et al., 2011). Furthermore, the 
hormone causes different transcriptional results in different cells based on the 
receptor isoform (Cheng et al., 2010). 
 Not only does thyroid hormone affect the embryonic development, its main 
function in an adult is the control of basal metabolic rate. This includes the 
amount of oxygen consumed and also the metabolism of vitamins, proteins, 
carbohydrates, and lipids. This occurs because some of the target genes that are 
affected transcriptionally by the hormone are genes that regulate 
gluconeogenesis, lipogenesis, insulin signaling, adenylate cyclase signaling, cell 
proliferation, and apoptosis (Oetting and Yen, 2007). Furthermore, it is known 
that people with thyroid problems experience muscle weakness and fatigue 
because T3 is critical for the development of skeletal muscle (O’Shea and 
Williams, 2002). Thyroid hormone is also important in the development of both 
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the auditory and visual systems. In order to achieve the proper development and 
differentiation of cones in the visual system, thyroid hormone must be present. 
The same goes for proper cochlea development because people with thyroid 
ailments often experience deafness and hearing impairment (O’Shea and 
Williams, 2002). Another organ whose development is dependent on thyroid 
hormone is the small intestine. Without proper thyroid hormone function, the 
intestinal crypt cells do not proliferate properly and intestinal maturation does not 
occur suitably, which negatively affects the brush border enzymes (O’Shea and 
Williams, 2002). Hence, nutrients are not appropriately absorbed which will have 
dire consequences for quite some time. 
 Since the liver contains TRbeta receptors, it can be expected that T3 play 
a necessary role in the liver. Not only is lipogenesis and gluconeogenesis 
influenced by thyroid hormone, but also cholesterol metabolism; numerous 
cholesterol complications are seen with thyroid hormone disorders (O’Shea and 
Williams, 2002). Two other biological functions affected by thyroid hormone are 
thermogenesis and cardiovascular functions. For example, cardiac conductance, 
muscle growth, and heart output are all impacted by thyroid hormones. When a 
patient suffers from hypothyroidism, they experience bradycardia and when they 
suffer from hyperthyroidism, they experience tachycardia. As previously 
mentioned thermogenesis is also controlled by thyroid hormone because there is 
less oxygen consumption and heat production in patients with hypothyroidism 
and vice versa in patients suffering from hyperthyroidism (O’Shea and Williams, 
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2002). Probably the greatest effect of thyroid hormone is in the development of 
the central nervous system. Without properly functioning thyroid hormone, the 
central nervous system does not develop properly and mental retardation can 
possibly occur (O’Shea and Williams, 2002). The focus of this study will be the 
effects of thyroid hormone on the skin, fibroblasts, and wound healing in general. 
This aspect has not been studied in detail and will be addressed later in this 
study. 
 As can be expected, there are many different physiological functions 
affected by thyroid diseases. Since iodine is crucial for the metabolism of thyroid 
hormone, iodine deficiencies are known to cause brain development issues in 
young children (Zimmermann and Andersson, 2012). Iodine deficiencies also 
cause thyroid goiters due to an overly stimulated thyroid gland by TSH. Simply 
adding iodine to the diet can prevent this, but adding iodine to the diet is difficult 
in less developed countries (Zimmermann and Andersson, 2012).  
 There are many problems associated with thyroid diseases. As expected, 
since thyroid hormone affects many diverse physiological functions, if a person 
suffers from either hyperthyroidism or hypothyroidism, many pathological 
characteristics are seen. Patients suffering from hyperthyroidism experience 
weight loss, increased metabolic rate, and tachycardia (Mittag et al., 2012).  It 
doesn’t matter how much the person eats, they will still experience weight loss 
because of the increase in metabolic rate. Conversely, a patient suffering from 
hypothyroidism will experience weight gain, bradychardia and a decreased 
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metabolic rate (Mittag et al., 2012). In addition to these symptoms, hyperthyroid 
patients also experience fatigue, palpitations, tremors and heat intolerance while 
hypothyroid patients show signs of cold intolerance (Pantalone and Nasr, 2010). 
Finally, since cardiac function is largely dependent on thyroid hormone, a 
common cause of heart failure in patients is thyroid hormone complications, both 
hyperthyroidism and hypothyroidism (Biondi, 2012). 
 For patients suffering from hypothyroidism, the condition is simply treated 
with thyroid hormone. Although, most patients receive treatments of thyroxine 
alone, it is unsure if this is the best mode of treatment. Studies have shown that 
patients respond better to treatments of thyroxine plus triiodothyronine 
(Bunevicius et al., 1999). Unfortunately, treating hyperthyroidism is not as 
straightforward as treating hypothyroidism. In the United States, Graves Disease 
is the most common cause of hyperthyroidism in patients. Graves disease is an 
autoimmune disease and occurs when T cells specific to thyroid-antigen, 
stimulate the thyroid and cause an overproduction of thyroid hormone. Instead of 
TSH stimulating the thyroid stimulating hormone receptor, or TSHR, these 
immune cells stimulate the receptors. Hence, despite the negative feedback 
causing low TSH, the TSHR are over stimulated by the T cells and this causes 
both hyperthyroidism and thyroid gland hyperplasia (Ponto and Kahaly, 2012). 
Treatment options for Graves Disease and hyperthyroidism in general, include 
surgical removal of parts of the gland, radioactive iodine treatment and anti-
thyroid drugs. Moreover, the individual symptoms can be treated in numerous 
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ways. For example, the tachycardia associated with hyperthyroidism can be 
treated with beta-blockers in order to relieve a patient suffering from the 
palpitations and tremors that accompany tachycardia (Pantalone and Nasr, 
2010).  
 
Wound Healing 
 One aspect of thyroid hormone that has not received much attention is its 
correlation with wound healing. The largest organ in the body is the skin, which is 
composed of the epidermis, the dermis, and the hypodermis (Chen et al., 2012). 
The outer most epidermis layer consists of stratified squamous keratinized 
epithelia and serves as a barrier for protection. The dermal layer on the other 
hand is comprised of connective tissue, mostly in the form of collagen. Certain 
structures, such as hair follicles and glands, protrude into the dermal layer 
deeply, even though they are derived from the epidermis (Martin, 1997). The skin 
serves as a necessary barrier and is the first line of defense against foreign 
materials. It serves an immune function and hence, if it is compromised through a 
lesion, it must be fixed efficiently. 
 When the skin develops a wound, there are many steps that take place to 
ensure the wound is properly addressed. The first step is hemostasis, which 
takes place when the platelets of the blood become activated (Yussof et al., 
2012). Skin wounds cause blood to leak from the vessels into the local tissues. In 
order to minimize this effect, hemostasis causes a temporary clot to form (Martin, 
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1997). When blood vessels are damaged, platelets go through a series of steps 
to allow them to stick together. This is known as primary hemostasis because it is 
the first response. The second aspect of hemostasis occurs when thrombin 
cleaves fibrinogen into its active form, fibrin and the clot now consists of platelets 
cross-linked with fibrin fibers. It should be known that this platelet plug is only 
temporary but it does act as a first response and signals the beginning of the 
more permanent wound healing processes (Martin, 1997). 
 The next step in the wound healing process is inflammation and it usually 
occurs within a day from the initial injury. It can even last for two weeks or even 
more depending on the circumstances (Yussof et al., 2012). In most standard 
cases involving wound healing, acute inflammation is the result. This is a very 
rapid response and the role of inflammation is to transport plasma proteins and 
leukocytes to the area of injury (Kumar et al., 2007). There are many reasons 
why the inflammatory process is triggered, with trauma being one of them. 
Initially, during the inflammatory process there is a change in the vasculature. For 
only a few seconds, there is a period of vasoconstriction, immediately followed by 
vasodilation. During the vasodilation, capillaries become distended which is the 
root cause for the erythema associated with inflammation. Also, as this occurs, 
the vasculature becomes more permeable and the plasma fluid leaks into the 
tissues (Kumar et al., 2007). As can be expected, the erythrocytes move more 
slowly through the vasculature because of the increase in viscosity. Neutrophils 
then gather at the endothelial surface and attach to the surface. After attaching to 
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the surface through rolling adhesion, they squeeze through the vasculature and 
migrate to the point of injury in the tissue. The neutrophils participate in killing 
bacteria and microbes through phagocytosis. Once they are located at the proper 
site of injury, they become activated to kill and digest the microbes through 
phagocytosis (Kumar et al., 2007). Following the invasion of neutrophils, the first 
responders, macrophages enter the site of injury to help in the phagocytosis 
process. Macrophages also release cytokines and growth factors, such as 
PDGF, TNF and TGF that help begin the proliferative process. Finally 
lymphocytes are recruited to the injury site, which participate in recruiting 
fibroblasts through the lymphocytes production of IL-2 (Yussof et al., 2012).  
 The next step of the wound healing process involves the migration and 
proliferation of fibroblasts. PDGF is released from both macrophages and 
platelets and causes fibroblasts to proliferate, migrate, and produce collagenase 
(Yussof et al., 2012). The role of fibroblasts is to lay down extracellular matrix, or 
ECM, in order to form support. Fibroblasts are known to lay down collagen, and 
this serves as a support protein. Furthermore, in order for the fibroblasts to 
migrate to the site of injury, they also produce proteolytic enzymes, such as 
matrix metalloproteinases. Once the fibroblasts have successfully migrated to the 
site of injury, they stop producing the metalloproteinases and begin producing 
collagen. The metalloproteinases allow for the migration, while the collagen 
allows for the wound to properly heal (Yussof et al., 2012). By day five of the 
injury, the fibroblasts have produced a special type of tissue known as 
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granulation tissue. This tissue is pink, soft, and granular and is also known as a 
scab. In this tissue, there are many fibroblasts, as well as capillaries that have 
formed through angiogenesis. This tissue contains loose ECM and as the days 
go on, more connective tissue is laid until a scar eventually forms (Kumar et al., 
2007). The actual wound closes up because the fibroblasts assume a 
myofibroblast like activity. They contain actin filaments and cause the contraction 
of the wound (Singer and Clark, 1999). As previously mentioned, through 
angiogenesis, new blood vasculature forms to replace the previously damaged 
vasculature. A large aspect of the formation of granulation tissue and 
angiogenesis occurs because of fibroblast growth factor, or FGF (Singer and 
Clark, 1999). When tissue is damaged, it experiences a lack of oxygen, or 
hypoxia, and FGF is released as a result, and this causes the formation of new 
vasculature. Endothelial cells also migrate and proliferate to the site of the injury 
and have a critical role in angiogenesis (Singer and Clark, 1999).  
 
Wound Healing Proteins 
 The two wound healing proteins of interest in this study are platelet-
derived growth factor-BB, or PDGF-BB and Integrin-β1. In general, PDGF 
induces mitosis of cells like fibroblasts, smooth muscle cells and others (Heldin 
and Westermark, 1999). There are four known isoforms that exist, A, B, C, and D 
and these isoforms can combine to form homo dimers or hetero dimers (Yoshida 
et al., 2012). An example of a homo dimer would be PDGF-BB, while an example 
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of a hetero dimer would be PDGF-AB. Additionally, there are two different forms 
of the PDGF receptor, the α and β, which can form hetero or homo dimers as 
well (Yoshida et al., 2012). Figure 2 shows all the possibilities of PDGF and 
PDGF receptors.  
 
 
Figure 2. PDGF Processing and Subsequent Isoforms. The A and B chains of PDGF are 
made from precursor chains. After the precursor chains are processed, the A and B chains are 
able to form hetero or homo dimers with the use of disulfide bridges. The figure also shows the 
different possibilities for the α and β isoforms of the PDGF receptor. The receptors also form 
dimers and the figure illustrates which chains of the PDGF molecule bind to which forms of the 
receptor. Finally, each PDGF dimer chain is able to bind to different receptor dimers with different 
specificity (Heldin and Westermark, 1999).  
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PDGF is produced in many different kinds of cells and the PDGF 
synthesis depends on distinct stimuli. For example, when a wound develops, and 
blood is lost, there is a loss in oxygen tension and as a result, PDGF is produced 
and released. Other stimuli that cause the production of PDGF include thrombin, 
growth factors and cytokines (Heldin and Westermark, 1999). PDGF-BB is 
extremely effective in causing the proliferation and migration of smooth muscle 
cells when acting through the β receptor and hence, is also a key component in 
the aspect of angiogenesis. The action of PDGF-BB on the β receptor is 
facilitated through the auto phosphorylation of the receptor (Malabanan et al., 
2012). 
 The other wound healing protein that will be covered is that of integrin-β1. 
As a whole, the integrins bind to fibronectin because they contain focal 
adhesions that are also found on fibroblasts, (Rossier et al., 2012). Integrins are 
transmembrane receptors that are bound in the extracellular matrix and much 
like the receptors for PDGF; integrin comes in the α and β form (Chen and 
Krasnow, 2012). Out of all the integrin isoforms, integrin-β1 is the most prevalent 
and effective extracellular matrix adhesion receptor. This receptor has a critical 
role in the differentiation of epithelial tissue and also collagen deposition; as can 
be expected since fibroblasts contain the integrin receptor. When the integrin-β1 
receptor is deleted in mice, pathologies occur that have to do with epithelial 
differentiation and uncontrolled proliferation (Yeh et al., 2012). 
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Thyroid Hormone and Wound Healing 
 Although thyroid hormone has been suggested as an agent for helping 
wounds because it upregulates certain growth factors and keratins, some studies 
do not support this positive therapeutic effect (Tarameshloo et al., 2011). Hence 
more research must be done in this field because if thyroid hormone does 
positively effect wound healing, then a topical thyroid cream could be 
revolutionary. The basis for this and future research lies in the fact that the skin 
and skin fibroblasts contain thyroid hormone receptors and an increase in thyroid 
hormone can alter keratin expression, pigmentation, and hair growth (Kassem et 
al., 2012). All three of the thyroid hormone receptor isoforms have been isolated 
in the skin tissues; more specifically, epidermal keratinocytes, fibroblasts, smooth 
muscle cells, endothelial cells, and cells of the hair follicle (Safer, 2011). Along 
with thyroid hormone receptors located in the skin, experiments have shown the 
conversion of T4 to both T3 and rT3 in skin cultures. Thus, this evidence 
suggests the existence of at least two different thyroid hormone deiodinases in 
the skin because type III deiodinase has been proven to convert T4 to rT3, while 
type II deiodinase converts T4 to T3 (Safer et al., 2003). Additionally, the skin 
complications of patients who suffer from hypothyroidism show that thyroid 
hormone plays an immense role in the skin. When dealing with the epidermis, 
hypothyroid patients have rough, scaly skin and also experience very dry skin on 
the palms of the hands and soles of the feet. The dermis of the skin is also 
negatively affected because the water content in the dermis causes the skin to 
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look pale in color. As determined in multiple studies, thyroid hormone is positively 
correlated with expression of epidermal keratinocytes and dermal fibroblasts 
(Safer, 2011). Hence, there is a distinct possibility that the use of topical thyroid 
cream will help in the wound healing process. 
 Even though the importance of thyroid hormone on wound healing has 
been contradictory, there have been experiments that show the benefits of 
topical thyroid hormone. One of these experiments involved comparing the 
effectiveness of wound healing in mice suffering from hypothyroidism and mice 
with no thyroid deficiencies (Safer et al., 2004). In this study, the experimental 
hypothyroid mice had a thyroid hormone level 16% that of the control mice and 
suffered from poorer wound healing than the control mice (Safer et al., 2004). 
This study was successful in showing that mice with hypothyroidism did not 
experience the proper level of wound healing and thyroid hormone must play a 
necessary role in the wound healing process. Once determining the importance 
of thyroid hormone, experiments were run in which topical thyroid hormone was 
added to the wounds of a set of experimental mice, while the control group 
received no such cream (Safer et al., 2005). This study showed that the mice 
treated with topical thyroid hormone experienced much higher wound healing 
efficiency than the mice that were not treated with thyroid hormone. By day four, 
the mice treated with the cream had wounds heal 50 mm2, and these wounds 
were 37.4% that of the original wound. Meanwhile, mice that were not treated 
only had wounds heal 32 mm2, and they were still 59.6% of their original size. 
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This can be seen in Figure 3 (Safer et al., 2005). This same experiment was run 
on guinea pigs because guinea pigs have a skin histology more similar to 
humans than mice, and it was also found that thyroid hormone increased healing 
(Kassem et al., 2012). 
 
Figure 3. Wound Healing Affected by Topical Thyroid Hormone. A. Baseline wounds (left) of 
both the control group and the experimental group. B. Wounds (right) of the same mice after four 
days. The wounds on the left were the control group and received no thyroid hormone cream, 
while the wounds on the right received topical thyroid cream. C. Amount of healing that took place 
4 days after the wounding for the control group (Vehicle) and the Treatment group (T3 Rx). The 
control group still had a wound size 59.6% of their original size while the treatment group was 
only 37.4% of their original size (Figure taken from Safer et al., 2005). 
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OBJECTIVES 
 Despite a complete consensus, there seems to be evidence showing that 
thyroid hormone does in fact positively affect the wound healing process. As 
mentioned previously, studies have shown that mice with hypothyroidism didn’t 
heal as well as mice without thyroid hormone deficiencies. Different studies also 
showed the effectiveness of applying a topical thyroid cream to the wounds of 
mice. Therefore, more studies need to be done on this subject because a topical 
thyroid cream can be extremely innovative and helpful, especially when dealing 
with patients whose wound healing is already compromised, such as diabetics.  
 Since studies have already been run on animals, it is imperative to move 
forward. Our study objectives are to find out which wound healing proteins 
become upregulated in fibroblasts dosed with T3. There are many different 
proteins associated within each step in the wound healing process, which include 
inflammation, proliferation, migration, and angiogenesis. In this specific study, 
PDGF-BB is the protein of interest. We are dosing fibroblasts with increasing 
concentrations of T3 and looking at the expression of PDGF-BB. Now that we 
know thyroid hormone has a positive effect on wound healing, it is critical to find 
the specific mechanisms that T3 acts upon.   
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METHODS 
Cell Passing 
 Initially, we received a stock plate of human skin fibroblasts from a lab 
assistant and had to grow them on four separate petri dishes. The materials 
needed for this included EDTA, trypsin, and media. EDTA solution was made 
from 100 mg EDTA stock powder (Cat# AM9260G, Invitrogen) and 500 mL 
phosphate buffered saline (PBS). The media consisted of DMEM (Cat#12430-
054, Gibco Life Technologies), fetal bovine serum (FBS) (Cat# SH30088.03, 
HyClone ThermoScientific), and 1% amphotericin B antibiotic (Cat# 17-745E, 
Lonza). The first step was to warm the solutions in a 30 degree Celsius water 
bath and sterilize all materials using 70% ethanol.  
 In the hood, three milliliters of EDTA are added to the stock plate in order 
to wash and sequester the metallic ions in the fibroblast plate. The EDTA is 
removed and soon after, three milliliters of trypsin (Cat# T4549-100ML, Sigma-
Aldrich Co.) are added and the plate is placed in the incubator for five to ten 
minutes. After the incubation period, three milliliters of media are added to 
neutralize the trypsin. Using a ten-milliliter pipette, the fibroblast solution is 
pipetted up and down to dislodge the fibroblasts and the cells are removed from 
the petri dish and placed into a fifteen-milliliter centrifuge tube. The centrifuge 
tube is spun at 1200 RPM for five minutes. Five separate petri dishes are labeled 
with the name, date, cell type, and thyroid hormone dilution. Furthermore, nine 
milliliters of media are added to these five separate petri dishes. When the 
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centrifuging of the fibroblast solution is complete, the supernatant liquid is 
removed. One milliliter of media should be added for each experimental plate 
and .75 of a milliliter for the stock plate. For example, there are five total petri 
dishes; four of them are experimental plates and one is a stock plate and 
therefore, a total of 4.75 milliliters of media will be added to the fibroblast pellet. 
Since all of these plates already contained nine milliliters of media, the final sum 
of media will contain ten milliliters for the experimental plates and 9.75 milliliters 
for the stock plate. Finally, these plates are placed in the incubator for multiple 
days, until the fibroblast confluence is at least 80%; a microscope is used to 
check the confluence. It usually takes around a week for the confluence to reach 
at least 80% and during this incubation period, the media of the plates are 
changed every two to three days. 
 
Cell Dosing 
 The necessary materials are the experimental fibroblast plates, sterile 1X 
PBS, media, T3 stock solution, and double stripped serum, or DSS. To make the 
DSS, 500 milliliters of FBS, 25 grams of resin (Cat# 142-2822, Bio-Rad 
Laboratories), and 15 grams of activated charcoal (Cat# 242276, Sigma-Aldrich 
Co.) are added to a 1-liter sterile, autoclaved jar. This solution shakes overnight 
with a stir bar at 4 degrees Celsius. After shaking, the contents are poured 
evenly into Falcon 50 milliliter tubes and then centrifuged at 9000 RPM for 20 
minutes at 4 degrees Celsius. The supernatant liquid should then be combined 
 24 
with more resin; the ratio of resin is 25 g of resin per 500 milliliters of 
supernatant. This new solution will be stirred with a stir bar at 4 degrees Celsius 
for five hours and then centrifuged at 9000 RPM at 4 degrees Celsius for 20 
minutes. The supernatant liquid will then be filtered using sterile filtered paper 
and frozen until future use. When making the T3 stock solution, 7 milligrams of 
95% T3 powder (Cat# 06B262013, ICN Pharmaceuticals) is combined with 4 
milliliters of deionized water and 40 microliters of NaOH. Once dissolved, 
deionized water is added to a total volume of 10 milliliters, forming a 10-3 M stock 
solution, and this solution can be stored in the freezer. The 1X PBS is diluted 
from stock 10X and run through a sterile filter.  
After the solutions are warmed properly to 30 degrees Celsius, three 
milliliters of the PBS are added to all of the plates and removed. This step is 
repeated two more times. After the PBS washes, ten milliliters of media are 
added to the four of the experimental plates. The four plates are labeled 
according to the dosage of T3. In order to achieve the proper dilutions, a 
completely separate plate is filled with ten milliliters of media and ten microliters 
of the stock 10-3 M T3 solution are added to this plate, forming a 10-6 M T3 
dilution. From the 10-6 M dilution, add 1 milliliter to the experimental fibroblast 
labeled 10-7 M; this will give a 10-7 M T3 dilution. To get a 10-8 M T3 dilution, 100 
microliters of the 10-6 M solution are added to the ten-milliliter fibroblast 
experimental plate with the 10-8 M label. Finally, to obtain a 10-9 M T3 dilution, ten 
microliters of the 10-6 M T3 solution are added to the ten-milliliter fibroblast 
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experimental plate labeled 10-9 M. Now we have our necessary T3 dilutions, and 
100 microliters of DSS are added to all four experimental plates, including the 
plate without any thyroid hormone. Finally, all four plates are placed in the 
incubator overnight.  
 
Cell Lysis 
 The final step of the fibroblast cell preparation is lysing the dosed 
fibroblasts. The materials needed for the lysing include the four experimental 
dosed fibroblasts plates, EDTA, trypsin, lysis buffer, media, a beaker filled with 
70% ethanol, a cell scraper, and a Styrofoam cooler with ice packs. To make the 
lysis buffer, one tablet of protease inhibitor cocktail (Cat# 11836153001, Roche 
Diagnostics) is dissolved in ten milliliters of Ripa buffer (Cat# R0278-500ML, 
Sigma-Aldrich Co.) and kept on ice. Next, the media is removed from the 
experimental plates, and EDTA is added to all four plates and removed. Three 
milliliters of trypsin are added to each plate and placed in the incubator for five 
minutes. Subsequently, three milliliters of media were added to each plate to 
neutralize the trypsin. After, each plate is scraped with the cell scraper by tilting 
the plate up and scraping the plate from top to bottom. Using a ten-milliliter 
pipette, the solution is pipetted up and down multiple times to dislodge the cells 
and this solution is placed into a labeled fifteen-milliliter centrifuge tube. This step 
is repeated for each experimental plate and it is critical the cell scraper is 
sterilized in ethanol before each scraping. The centrifuge tubes are centrifuged 
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for five minutes at 1200 RPM; after completion, the supernatant liquid in each 
tube is removed and it is imperative the pellet is not disturbed with the vacuum. 
Thereafter, 250 microliters of the cold lysis buffer are added to each tube and 
each pellet is re-suspended in the lysis buffer. These new solutions containing 
250 microliters of lysis buffer and the dosed fibroblasts are placed on ice for 
around fifteen minutes. After fifteen minutes, the solutions from the four tubes are 
placed into four-labeled eppindorf tubes and the tubes are centrifuged at 13,000 
RPM at 4 degrees Celsius for ten minutes. Following this spinning period, the 
supernatant liquid is collected with a micropipette and placed into labeled 
eppindorf tubes; the pellet must not be disturbed in this step because it contains 
the cell membranes that can interfere in the experiments. These labeled 
eppindorf tubes with the dosed, lysed fibroblasts must be stored at -80 degrees 
Celsius.  
 
Western Blot 
Buffers 
 Once the cells are properly passed, dosed, and lysed, we can run our 
western blots in order to find out which proteins are being expressed. The first 
step in performing a western blot is producing the proper buffers: the transfer 
buffer and the running buffer. The 10X transfer buffer is made by dissolving 30.3 
grams of tris base (Cat# 69L-9053, Fisher Scientific) and 144 grams of glycine 
(Cat# 521M-12294, Fisher Scientific) in one liter of deionized water. Making the 
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1X transfer buffer entails mixing 100 milliliters of the 10X stock transfer buffer, 
200 milliliters of methanol (Cat# 1700L6808, Fisher Scientific) and 700 milliliters 
of deionized water; this solution must be refrigerated because it needs to be cold 
before it is used. To make the running buffer, 50 milliliters of 20X running buffer 
(Cat# NP0002, Invitrogen) is mixed with 950 milliliters of deionized water.  
 
Gel Electrophoresis 
 The dosed, lysed fibroblasts are subsequently defrosted and prepared by 
mixing 5 microliters of DDT/sample reducing agent (Cat# NP0009, Invitrogen), 
12.5 microliters of LDS (Cat# NP0007, Invitrogen) and 32.5 microliters of the 
lysed fibroblasts. This step is repeated three more times so the end result is four 
prepared samples; one tube will contain fibroblasts with no T3, one will contain a 
10-9 M concentration, one with 10-8 M concentration and the final tube will contain 
fibroblasts with a 10-7 M concentration. Next, the tubes with the sample/DDT/LDS 
solution are placed in a 70 degree Celsius hot water bath for ten minutes. The 
electrophoresis running gel box can be set up by removing the tape and comb 
from the NuPAGE Bis-Tris gel (Cat# NP0322, Invitrogen) and loading the gel into 
the front of the box. A blank gel, or a second gel is loaded into the back of the gel 
box and they are locked into place. The previously made running buffer should 
be poured into the middle chamber of the box, allowing it to overflow to the top of 
the outer chambers and 500 microliters of NuPAGE antioxidant (Cat# NP0005, 
Invitrogen) will be added to the middle chamber. After the ten-minute warming 
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period, the samples can be loaded into the wells of the gels. In the first well, 
fifteen microliters of ladder (Cat# LC5925, Invitrogen) are loaded and fifteen 
microliters of the four samples are loaded in the subsequent four wells. Since 
there are multiple empty wells in the gel, the four samples can be loaded once 
again in case something goes awry with the first wells. The gel is run at 164 volts 
for around 35-40 minutes, or until the samples have traveled a sufficient 
distance; if the samples run unevenly, the voltage can simply be turned down. 
 
Membrane Transfer 
 Once the gel has finished running, the gel has to be transferred onto the 
more stable nitrocellulose membrane (Cat# LC2001, Novex Life Technologies). 
The gel is removed from the plastic case, trimmed and placed into the transfer 
cassette. The proper orientation of the transfer case is as follows; clear side of 
the cassette, sponge, filter paper, membrane, gel, filter paper, sponge, and black 
side of the cassette. Before the membrane is placed over the gel, it is 
recommended that it be dipped in the transfer buffer for a second in order to 
prevent air bubbles between the membrane and gel. Next, the entire transfer 
cassette is placed in the transfer box, which is filled with the 1X transfer buffer. 
The clear side of the cassette facing the red side of the box and the black side of 
the cassette facing the black side of the box. The transfer is run at 220 milliamps 
for 50 minutes. 
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Membrane Blocking and Antibody Incubation 
  The powdered milk solution can be prepared by mixing 5 milliliters of 
powdered milk and 100 milliliters of 1X TBST, which produces the 5% powdered 
milk solution. Mixing 10 milliliters of the 5% milk solution with 40 milliliters of 
TBST produces a 1% milk solution. Mixing 24.2 grams of tris base, 80 grams of 
NaCl, 38 milliliters of HCl, and 10 milliliters of tween 20 produces 10X TBST. The 
10X TBST must be at a pH of 7.6 and this 10X TBST is diluted to 1X using 
deionized water.  
After the 50-minute transfer stage, the membrane is removed, and placed 
into a blotting box. The subsequent step is the blocking step to avoid unspecific 
antibody binding. 5% milk is poured over the membrane in the blotting box and 
the membrane is shaken at room temperature for an hour. After blocking, the 
primary antibodies are added to the membrane; we found that a 1:1000 antibody 
dilution works best. To achieve this, 6 microliters of the necessary primary 
antibody, Beta-actin (Cat# 8H10D10, Cell Signaling Technology), and PDGF-BB 
(R & D Systems) are added to 6 milliliters of 5% milk and this solution is poured 
into the membrane-blotting box. The box must be shaken overnight in a cold 
room and this step marks the end of the first day of the western blot. 
 Day two of the western blot begins by removing and saving the primary 
antibody solution because the solution can be reused multiple times if frozen. 
After the collection of the antibody solution, the membrane is washed with 1X 
TBST three different times for five minutes each. Now, the secondary antibody 
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solution can be added to the box and shaken at room temperature for an hour. 
The dilution of the secondary antibody is variable and after many attempts, we 
found that the anti-mouse secondary antibody should be added in a 1:5000 
dilution and the anti-rabbit secondary antibody should be added in a 1:2000 
dilution. The anti-mouse antibody dilution is prepared by adding 1.2 microliters of 
the antibody to 6 milliliters of the 1% powdered milk solution, while the anti-rabbit 
secondary dilution is prepared when 3 microliters of the antibody are added to 6 
milliliters of the 1% milk solution. Before adding the secondary antibody solution 
to the blotting box, it is necessary to centrifuge the solution at 1200 RPM for one 
minute. After the hour-long secondary antibody shake, there are three more five-
minute TBST washing periods to minimize nonspecific binding. When the washes 
are complete, two milliliters of each ECL solution (Cat# WP20005, Invitrogen) 
can be added to a separate clean blotting box. The membrane is then removed 
from the initial box using forceps and tapped on a paper towel to ensure the 
removal of excess TBST. The membrane can now be added to the blotting box 
containing the ECL solution and shaken for five minutes. Then, the membrane, 
along with the developing cassette, forceps, two plastic covering sheets, paper 
towels, and chemiluminescence photographic film (Cat# 28906835, GE 
Healthcare) is brought to a dark room containing a film developer. The excess 
ECL must be removed from the membrane and the membrane is placed between 
the two plastic sheets in the developing cassette. A piece of film is placed over 
the second plastic sheet and the developing case is closed tightly to ensure 
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proper developing time. The developing time can vary anywhere from a minute to 
thirty minutes depending on the antibody. After sufficient developing time, the film 
is run through the film developer and we can now see whether or not thyroid 
hormone caused an upregulation in wound healing proteins such as PDGF-BB.  
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RESULTS 
 Based on numerous western blots run, we can see a clear pattern in the 
expression of PDGF-BB in fibroblasts dosed with differing concentrations of 
thyroid hormone. In general, there is an upregulation in the expression of PDGF-
BB in the fibroblasts dosed with thyroid hormone compared to the fibroblasts 
containing no thyroid hormone. This shows that thyroid hormone could play and 
integral part in wound healing if these results hold true. However, the results do 
not appear to be dose dependent because the fibroblasts containing the least 
amount of thyroid hormone, 10-8 M, almost always contained a greater or equal 
expression in PDGF-BB than the fibroblasts containing the greater concentration 
of thyroid hormone, 10-7 M. 
 Table 1 shows a summary of the changes in PDGF-BB expression in all of 
the fibroblasts. Since beta-actin was the control protein for this experiment, the 
PDGF-BB bands were compared to those of the beta actin bands and the 
percent increase or decrease was noted. We simply looked at the heaviness of 
each band and noted a percentage that we felt fit with the band. Ideally, all of the 
bands for beta-actin would be equal in darkness since it was used as the control. 
However, this doesn’t always occur for a variety of reasons. For example, some 
fibroblasts samples may contain more fibroblasts than other samples. Hence, the 
sample with the greater number of fibroblasts will show heavier bands for every 
protein. For this reason, we compared the PDGF-BB band with that of the beta-
actin band for each concentration of thyroid hormone dosed fibroblasts. In 
 33 
addition, we gave each band an arbitrary number and noted the percentage 
increase or decrease of PDGF-BB from beta-actin. These percentages are also 
an average from all of the western blots that were run. Since numerous western 
blots were run, it made sense to average the percentage between all of them. 
Table 1. Percentage Change of PDGF-BB Bands in Comparison with B-actin Bands. Out of 
the entire western blots run, this table provides information regarding the percentage change of 
PDGF-BB in comparison to the control, beta-actin. These values are based on arbitrary numbers 
given to each individual band and a percentage was calculated based on these numbers. In 
addition, these percentages are the average of all the individual percentages of each western 
blot. 
 
 
 
 
100 M (control) 
 
 
5 % ± 4% 
 
10-8 M 
 
93 % ± 10% 
 
10-7 M 
 
72 % ± 10% 
 
As previously mentioned, Table 1 represents the average percentage 
change of PDGF-BB in comparison to the beta-actin bands. A smaller 
percentage correlates with a greater difference between the two bands. For 
example, on average, for the control fibroblasts, the PDGF-BB bands were 5/96th 
that of the beta-actin bands, which means the PDGF-BB bands for this group 
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were 5% that of the beta-actin bands. It is imperative to compare only the 
individual cells within a group and not between groups. For example, each 10-8 M 
sample was given a percentage separately and then they were averaged. The 
greater the percentage means the PDGF-BB band is closer to or potentially 
darker than the beta-actin band.  
 Based on the percentages shown in Table 1, it can be seen that there is a 
clear increase in PDGF-BB expression in fibroblasts dosed with thyroid hormone. 
For example, on average, the PDGF-BB band for the 10-8 M samples was 93% of 
the beta-actin band; almost equal band darkness. Some individual PDGF-BB 
bands were even 3 times that of the beta-actin bands. Hence, there was a 
definite increase in PDGF-BB expression for the 10-8 M samples in comparison to 
the control fibroblasts. The 10-7 M samples also showed an increase in the 
PDGF-BB expression in comparison to the control fibroblasts based on the 
numbers in Table 1. However, the expression of PDGF-BB does not seem to be 
dose dependent, as can be seen with the greater value for the 10-8 M samples in 
comparison to the 10-7 M samples: 93% and 72% respectively.  
 In order to see if the data was significant, two separate t-tests were run 
with a sample size of n=4. One was run comparing the control group and the 10-8 
M samples and another comparing the control group and the 10-7 M samples. 
When comparing the control group and 10-8 M fibroblasts, at 95% certainty, the 
calculated t-value was -1.25 while the p value was -2.4. Based on these values, 
the difference in PDGF-BB expression cannot be deemed statistically significant. 
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When comparing the control group and 10-7 M samples, at 95% certainty, the t-
value was -1.2, with a p-value of -2.4. Hence, this also shows that the difference 
in PDGF-BB expression between the groups is not statistically significant. Figure 
4 shows a representative western blot out of the many run. 
 
           A                           B 
 
 
Figure 4. Western Blot 1. Letters A and B show different samples run on the same gel. 
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DISCUSSION 
 After previous studies showed that applying topical thyroid cream to a 
wound led to quicker healing, the next logical step was to find out which specific 
wound healing proteins are affected by thyroid hormone. As mentioned, these 
experiments were run through western blots and the subsequent films were read 
to determine the affect of thyroid hormone. The protein of interest was PDGF-BB, 
which has a role in the proliferation and migration phases, and had a size of 
around 28 kDa. The films showed a faint band around 28 kDa when the exposure 
time was 2 minutes. The exposure time was increased to 8 minutes and 15 
minutes, and the bands became darker and easier to read.  
The fibroblasts dosed with thyroid hormone showed a darker band than 
the fibroblasts that were not dosed with thyroid hormone. As mentioned in the 
results section, PDGF-BB showed an upregulation in the fibroblasts dosed with 
thyroid hormone. However, this upregulation did not appear to be dose 
dependent because in general, PDGF-BB was expressed greater in the 10-8 M 
samples as opposed to the 10-7 M samples. This may occur for a few reasons 
however. The physiological concentration of thyroid hormone is around 10-9 M 
and a thyroid hormone concentration of 10-7 M may be too much thyroid 
hormone. 10-7 M is 100 fold greater than the physiological concentration, so it is 
very probable that this concentration was toxic to the fibroblasts and hence, not a 
viable environment. Therefore, if 10-7 M is somewhat toxic to the fibroblasts, than 
naturally, the PDGF-BB expression in these fibroblasts will be lower than the 
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expression in the 10-8 M fibroblasts. It is also entirely possible that a 
concentration of 10-8 M is ideal for the expression of PDGF-BB. This may be the 
concentration in which fibroblasts express PDGF-BB maximally. In order to be 
sure of this, more research needs to be done with different thyroid hormone 
concentrations. A concentration of 10-9 M should be used since this is the 
physiological concentration of thyroid hormone in the body and by using this 
concentration, we can figure out if the PDGF-BB expression is dose dependent, 
or which concentration leads to the greatest expression.  
 The results from this experiment are very promising and open the door for 
future experiments. PDGF-BB is a protein that is crucial for the proliferation and 
migration of fibroblasts. Experiments run on mice have shown that a topical 
thyroid cream is effective for the wound healing process and through our 
experiments, we have found a mechanism in which thyroid hormone acts. One 
reason that thyroid hormone speeds up the wound healing process is because it 
helps the proliferation and migration steps. In order to gain more insight into the 
effects of thyroid hormone, different proliferation and migration proteins should 
be studied. This way, we can see if thyroid hormone assists in these phases by 
upregulating other proteins, or if it simply achieves the goal through PDGF-BB. It 
should also be noted that the size of the bands were simply judged by the human 
eye and not a machine. Thus, it is possible that analysis contained errors since 
human error is always a possibility. However, using ones eyes can be just as 
effective and sometimes even more effective than using the machine. We had 
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several people look at the bands and we all came to the same conclusions. The 
biggest problem with using the human eye is making up arbitrary numbers and 
not having actual measurements provided by a machine. All in all, this 
experiment was successful and opens the door for more research on the topic. 
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